Resolian Appoints Rob Stachlewitz as CEO, Honggang Bi as Chairman of the Board, and Pat Bennett as Chief Business Officer and President of Scientific Affairs
Rhea-AI Summary
Resolian, a global bioanalytical and analytical sciences partner, announced key leadership changes. Rob Stachlewitz joins as CEO, while current CEO Pat Bennett transitions to Chief Business Officer and President of Scientific Affairs. Honggang Bi has been appointed Chairman of the Board. The company, backed by Ampersand Capital Partners and KKR, has expanded globally through acquisitions including Alliance Pharma, Drug Development Solutions, and Denali MedPharm, establishing operations across four continents. The reorganization aims to support growing client needs and enhance global operations.
Positive
- Global expansion through strategic acquisitions across four continents
- Strong financial backing from major investors (Ampersand Capital Partners and KKR)
- Experienced leadership team with combined decades of industry expertise
Negative
- None.
News Market Reaction – KKR
In the trading session that priced this news, KKR declined 1.01%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
New leadership and reorganization will foster the next chapter of growth and enhance business operations to best support evolving client and CRO partner needs on a global scale.
Backed by
"It's an honor to be appointed Chairman of Resolian. I am excited to work alongside Rob, Pat, the Ampersand and KKR teams, and our nearly 500 dedicated global employees. Resolian is an innovative, global, bioanalytical and analytical CRO. I am confident we have the leadership, vision and dedicated quality-driven team to execute our clients' therapeutic programs," said Honggang Bi. Newly-appointed Chairman Honggang Bi posesses a more than 30 year illustrious career with Pfizer, Covance and Labcorp, leading their drug development operations across multiple geographies.
Incoming CEO Rob Stachlewitz joins Resolian with an impressive track record, having most recently served as Corporate Vice President and General Manager at Charles River, where he oversaw their largest site. Rob brings 15 years of pharmaceutical R&D experience, having held key roles at Boehringer Ingelheim, Abbott Laboratories, and Procter & Gamble. As CEO, Rob will guide Resolian through its next phase of strategic growth, enhancing its operational capabilities and global presence.
"With Rob's extensive background shepherding life science businesses and teams on a global scale, we are confident that he will lead Resolian to new heights as we continue to expand our bioanalytical operations," added Honggang Bi. Rob holds a PhD from the University of
Pat Bennett, who has led Resolian for nearly three years, has been instrumental in strategically positioning and steering the organization through a dynamic and transformative period, harmonizing operations, and driving global expansion. As Chief Business Officer and President of Scientific Affairs, Pat will focus on growing new service capabilities and enhancing customer relationships, leveraging his 30+ years of experience in bioanalytical sciences and business development. Pat will also oversee several critical functions to foster client collaboration and synergies across the Resolian team.
"We are incredibly grateful for Pat's leadership during a pivotal time in Resolian's history," said Dave Patteson, Partner, Ampersand Capital Partners. "As he transitions into his new role, Pat will continue to make critical contributions to Resolian's future growth and innovation. The combined leadership of Honggang, Rob and Pat is unrivaled in the bioanalytical CRO industry. The Resolian team will provide industry leading bioanalytical services to clients for their drug development projects across all major geographies."
About Resolian
Resolian (formerly Alliance Pharma Inc., Drug Development Solutions Ltd. and Chongqing Denali Medpharma, Ltd.) is a leading global research laboratory that provides specialized services in GxP and nonregulated bioanalysis, drug metabolism/pharmacokinetics (DMPK), and GMP CMC analytical and materials science. Nearly 500 experts across the
About Ampersand Capital Partners
Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with
About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/resolian-appoints-rob-stachlewitz-as-ceo-honggang-bi-as-chairman-of-the-board-and-pat-bennett-as-chief-business-officer-and-president-of-scientific-affairs-302289255.html
SOURCE Resolian